June 1, 2015 / 5:20 AM / 2 years ago

BRIEF-Interim data support safety and efficacy of Pharming Group's RUCONEST

1 Min Read

June 1 (Reuters) - Pharming Group NV :

* Announces interim results from the ongoing phase II pediatric clinical trial of RUCONEST

* Interim data from ongoing pediatric clinical trial and results from a clinical immunology study support safety and efficacy of RUCONEST

* Several abstracts presented demonstrate Pharming's ongoing commitment to advance innovative science in Hereditary Angioedema (HAE)

* "These data add to our clinical database and post-marketing experience that demonstrate a very low risk of allergy with rhC1INH exposure" - Chief Operating officer Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below